Giray Bulut
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Giray Bulut has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Birsen Can Demirdöğen
Department of Biomedical Engineering, TOBB University of Economics and Technology, Ankara, Turkey
1 shared publication - Eda Sezer
Faculty of Medicine Southampton General Hospital University of Southampton Southampton SO16 6YD UK southampton.ac.uk
1 shared publication - Emre Evin
Department of Biological Sciences, Faculty of Science, Middle East Technical University, Ankara, 06800, Turkey
1 shared publication - Merve Akkulak
Orta Doğu Teknik Üniversitesi
1 shared publication - Orhan Adalı
Department of Biological Sciences, Faculty of Science, Middle East Technical University, Ankara, 06800, Turkey
1 shared publication Şeref Demirkaya
Department of Neurology, University of Health Sciences, Gülhane Health Sciences Institute, Ankara, Turkey
1 shared publication
Latest Publications
- 21 September 2021
- Published by Springer Nature in Neurological Sciences
- Vol. 43 (4) , 2611-2620
Association of cholesterol 7α-hydroxylase (CYP7A1) promoter polymorphism (rs3808607) and cholesterol 24S-hydroxylase (CYP46A1) intron 2 polymorphism (rs754203) with serum lipids, vitamin D levels, and multiple sclerosis risk in the Turkish population
Background Patients with multiple sclerosis (MS) have significantly lower vitamin D levels. Cholesterol is known to be the precursor for vitamin D synthesis, and cholesterol removal is regulated by cholesterol 7α-hydroxylase (CYP7A1) in the liver and cholesterol 24S-hydroxylase (CYP46A1) in the brain. In this study, single nucleotide polymorphisms (SNPs) within the genes CYP7A1 (rs3808607) and CYP46A1 (rs754203) were investigated for their effects on serum lipid profiles, vitamin D levels, and the risk of developing MS. Methods Patients with MS (n = 191) and controls (n = 100) were tested using the PCR–RFLP method to determine their genotypes for rs3808607 and rs754203 SNPs. Results The minor (C) allele frequency for CYP7A1 rs3808607 variation was 0.380 in patients with MS and 0.305 in control subjects (P = .074). For CYP46A1 rs754203, the frequencies of the minor (C) allele were 0.272 and 0.250 in patients and control subjects, respectively (P = .563). Serum vitamin D (25(OH)D3) concentrations were significantly lower in patients than in control subjects (P = .002). The CYP46A1 rs754203 SNP was associated with total cholesterol levels in patients, whereas the CYP7A1 rs3808607 variant was not associated with serum lipid parameters or vitamin D levels in patients or control subjects. Conclusion CYP7A1 rs3808607 and CYP46A1 rs754203 variations are not likely to confer an independent risk for MS development in the Turkish population. To the best of our knowledge, this is the first study to investigate the association between CYP46A1 rs754203 and MS risk.
- 21 September 2021
- Published by Springer Nature in Neurological Sciences
- Vol. 43 (4) , 2611-2620
Association of cholesterol 7α-hydroxylase (CYP7A1) promoter polymorphism (rs3808607) and cholesterol 24S-hydroxylase (CYP46A1) intron 2 polymorphism (rs754203) with serum lipids, vitamin D levels, and multiple sclerosis risk in the Turkish population
Background Patients with multiple sclerosis (MS) have significantly lower vitamin D levels. Cholesterol is known to be the precursor for vitamin D synthesis, and cholesterol removal is regulated by cholesterol 7α-hydroxylase (CYP7A1) in the liver and cholesterol 24S-hydroxylase (CYP46A1) in the brain. In this study, single nucleotide polymorphisms (SNPs) within the genes CYP7A1 (rs3808607) and CYP46A1 (rs754203) were investigated for their effects on serum lipid profiles, vitamin D levels, and the risk of developing MS. Methods Patients with MS (n = 191) and controls (n = 100) were tested using the PCR–RFLP method to determine their genotypes for rs3808607 and rs754203 SNPs. Results The minor (C) allele frequency for CYP7A1 rs3808607 variation was 0.380 in patients with MS and 0.305 in control subjects (P = .074). For CYP46A1 rs754203, the frequencies of the minor (C) allele were 0.272 and 0.250 in patients and control subjects, respectively (P = .563). Serum vitamin D (25(OH)D3) concentrations were significantly lower in patients than in control subjects (P = .002). The CYP46A1 rs754203 SNP was associated with total cholesterol levels in patients, whereas the CYP7A1 rs3808607 variant was not associated with serum lipid parameters or vitamin D levels in patients or control subjects. Conclusion CYP7A1 rs3808607 and CYP46A1 rs754203 variations are not likely to confer an independent risk for MS development in the Turkish population. To the best of our knowledge, this is the first study to investigate the association between CYP46A1 rs754203 and MS risk.